56 BLA 125742 0 08 09 2021 Telecon Information Reques

Pfizer Documents (PHMPT/FDA)

Pfizer Bla Submission

Pfizer 16 Plus Documents

2

Document text

From:  Smith, Michael (CBER)  
Sent:  Monday, August 9, 2021 12:06 PM  
To: Harkins Tull, Elisa <[email protected]>; Aghajani Memar, Neda 
<[email protected]>; Devlin, Carmel M <[email protected]> 
Cc: Naik, Ramachandra <[email protected]>; Gottschalk, Laura 
<[email protected]>  
Subject:  STN 125742.0: Clinical IR RE sequencing data  
 
Elisa,  
 
The review team has the below clinical questions for you regarding study C4591001.   Please respond as soon as possible and no later than Thursday, August 
12, 2021.    
 One subject in the vaccine group, (Site No:   1252, Subject No:   12521010): 80-
year -old white, non- Hispanic male who received two doses of BNT162b2 (17 Aug 
2020 and 08 September 2020), died from COVID pneumonia.  
 
If available, please provide sequencing data for the virus isolated fr om this 
patient.  
 If there is available genomic sequencing data for any other COVID -19 case, 
especially those with fatal outcomes, and those from HIV positive subjects, please 
submit that information.  
 
 
Regards,  
  Mike  
  
- Please confirm receipt of this e -mail and let us know if you have any 
questions.  
  
Mike Smith, Ph.D.  
Captain, USPHS  
 
Senior Regulatory Review Officer  
Food and Drug Administration  
Center for Biologics Evaluation & Research  
Office of Vaccines Research & Review  
Division of Vaccines and Related  Products Applications  
Tel: 301- 796-2640  
[email protected]  
FDA-CBER-2021-5683-1024771
 
 
         
  
  
THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS 
ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND 
PROTECTED FROM DISCLOSURE UNDER LAW.  If you are not the addressee, or a 
person authorized to deliver the document to the addressee, you are hereby 
notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized.   If you have 
received this document in error, please immediately notify the sender immediately by e- mail or phone.
 
  
  
  
 
FDA-CBER-2021-5683-1024772